Can we predict early treatment discontinuation on immune checkpoint therapy?

A look at the clinical features that predict for early discontinuation with checkpoint blockade in ovarian cancer

March 28, 2018

On APHINITY, SOLO2 and Immunomedics

Reader Q&A on women's cancers relating to HER2, PARP and TNBC...

February 13, 2017

Asking Good Questions is both an Art and a Science

Latest BSB reader Q&A looks at 5 questions from subscribers

March 16, 2017

FDA Approval of Niraparib is a Failure for Precision Medicine

The third PARP inhibitor in ovarian cancer hits the market - what's the latest story?

March 27, 2017

A potentially encouraging IO combination approach

What can we learn from the early data exploring PARPi plus checkpoint blockade combinations in ovarian cancer?

March 26, 2018